Cancer Trials Ireland > Cancer Trials > Lung > 22-23 NeoCOAST-2

22-23 NeoCOAST-2

About this trial

NeoCOAST-2 is a Phase 2, open-label, multicentre, randomised, two-arm study of
durvalumab + monalizumab / oleclumab + CTX. The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab or AZD0171 and platinum doublet chemotherapy; or MEDI5752 in combination with platinum doublet chemotherapy or datopotamab deruxtecan (Dato-DXd) in combination with durvalumab and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

Patient Profile

  1. Newly diagnosed and previously untreated NSCLC.
  2. Resectable, Stage IIA to Stage IIIA (per IASLC Staging).
  3. ECOG PS 0-1.
  4. Tumour samples must be available or obtainable.
  5. Surgery may be lobectomy, sleeve resection or bilobectomy, no pneumonectomy, segmentectomies or wedge resection.
  6. FEV1 of 1.0 L and DLCO >40%

Where’s this trial being run?

Beaumont Hospital, St James’s Hospital, University Hospital Galway, and Mater Private Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: 22-23 NeoCOAST-2
Number: 22-23
Full Title:

A Phase II Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer
Principal Investigator: Prof Jarushka Naidoo
Type: Industry Sponsored
Sponsor:

AstraZeneca
Recruitment Started: Global: Yes
Ireland: Yes
Global Recruitment Target: 350
Ireland Recruitment Target: 15+